HIV PrEP: What Pre-Exposure Prevention Means

PrEP is medicine used before possible HIV exposure as part of prevention care. It is different from treatment of HIV and from emergency care after a possible exposure.

The key distinction

Research has examined different preparations and delivery methods, including long-acting options. A promising trial does not remove the need for appropriate testing, eligibility assessment, follow-up, or a discussion of access and preferences. Prevention of HIV is also not the same as preventing every other sexually transmitted infection or pregnancy. These distinctions are more useful than treating a product as universal protection.

What the research adds

A 2025 New England Journal of Medicine phase 3 trial examined a long-acting HIV-prevention medicine in men and gender-diverse people. HIV incidence was lower in the study intervention group than its specified comparisons. The trial was manufacturer-funded and involved defined eligibility, testing, and follow-up requirements. Read the journal source.

A trial result is not a guarantee of protection in every circumstance or a personal prescription. Eligibility, access, testing, interactions, adherence, and ongoing follow-up matter. HIV prevention and prevention of other sexually transmitted infections must also be distinguished.

A useful next step

If you want to discuss prevention, ask a qualified healthcare professional about currently available options and what ongoing care they involve. This article does not decide eligibility, provide a regimen, or recommend a medicine. If an exposure may already have happened recently, seek prompt professional assessment rather than waiting to arrange routine PrEP; a different time-sensitive prevention question may apply. Check current official guidance because available products and local recommendations can change. The source describes a trial, not a guarantee of protection for every situation.

Questions to consider

• Is the question about prevention before exposure or urgent care after it?
• What assessment and ongoing follow-up are needed?
• What other prevention needs should be considered separately?

Sources and further reading

• Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. (2025) - The New England journal of medicine.
• Preventing HIV with PrEP - Centers for Disease Control and Prevention.

Health disclaimer

This article is for general education only. Its information and suggestions are not medical advice, diagnosis, or treatment and may not be right for everyone. Ask a qualified health professional for advice that fits your health, medications, and needs before making changes to your care or acting on health suggestions. Do not delay professional care because of this article.